BIIB vs. PFE: Biogen vs. Pfizer Stock Comparison

November 11, 2026

How do Biogen (BIIB) and Pfizer (PFE) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Biogen (BIIB) and Pfizer (PFE) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BIIB is classified in Biotechnology while PFE is classified in Pharmaceuticals.

Company profile comparison for Biogen (BIIB) and Pfizer (PFE)
Profile Item	BIIB	PFE
Name	Biogen Inc.	Pfizer Inc.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Pharmaceuticals
GICS Sub-Industry	Biotechnology	Pharmaceuticals
Market Capitalization	36.71 billion USD	167.52 billion USD
Currency	USD	USD
Exchange	Nasdaq	NYSE
Listing Date	September 17, 1991	June 1, 1972
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

BIIB

PFE

GSPC

Biogen (BIIB) vs. Pfizer (PFE), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Biogen (BIIB) and Pfizer (PFE). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Biogen (BIIB) and Pfizer (PFE). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Biogen (BIIB) and Pfizer (PFE)
Metric	BIIB	PFE
Total Return (1Y)	65.44%	28.65%
Total Return (3Y, Annualized)	4.62%	6.41%
Total Return (5Y, Annualized)	-0.96%	-3.98%

Risk Profile

Drawdown History

BIIB

PFE

GSPC

Biogen (BIIB) vs. Pfizer (PFE), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Biogen (BIIB) and Pfizer (PFE). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Biogen (BIIB) and Pfizer (PFE)
Metric	BIIB	PFE
Volatility (1Y, Annualized)	34.58%	21.72%
Beta (5Y)	0.08	0.35
Max Drawdown (5Y)	-64.35%	-58.96%
Avg. Volume (3M)	1.05M	33.67M

Risk-Adjusted Performance

Risk-Return Positioning

BIIB and PFE are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Biogen (BIIB) and Pfizer (PFE)
Metric	BIIB	PFE
Sharpe Ratio (1Y)	1.77	1.12
Sortino Ratio (1Y)	2.77	1.73

Profitability

ROE (TTM)

Both Biogen (BIIB) at 1.87% and Pfizer (PFE) at 4.47% land near their industries’ usual ROE ranges, so capital efficiency looks broadly in line with peers on both sides.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.87%

Max: 109.18%
Q3: 6.23%
BIIB: 1.87%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.47%

Max: 109.18%
Q3: 6.23%
PFE: 4.47%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Biogen (BIIB) vs. Pfizer (PFE): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Pfizer (PFE) at 6.34% retains a top-quartile share of revenue as profit, ahead of Biogen (BIIB) at 3.38%, which keeps about the industry-typical share.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.38%

Max: 18.05%
Q3: 4.78%
BIIB: 3.38%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.34%

Max: 18.05%
PFE: 6.34%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Biogen (BIIB) vs. Pfizer (PFE): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Biogen (BIIB) at 24.12% and Pfizer (PFE) at 33.38% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

24.12%

Max: 83.12%
BIIB: 24.12%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

33.38%

Max: 83.12%
PFE: 33.38%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Biogen (BIIB) vs. Pfizer (PFE): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Biogen (BIIB) and Pfizer (PFE)
Metric	BIIB	PFE
ROE (TTM)	1.87%	4.47%
ROA (TTM)	4.94%	5.59%
Net Margin (TTM)	3.38%	6.34%
Operating Margin (TTM)	24.12%	33.38%
Gross Margin (TTM)	75.77%	74.90%

Growth

Revenue Growth

Biogen (BIIB) at 2.22% is around its peer norm for revenue growth, while Pfizer (PFE) at -1.65% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Biogen (BIIB) vs. Pfizer (PFE): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both Biogen (BIIB) at -21.38% and Pfizer (PFE) at -3.55% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Biogen (BIIB) vs. Pfizer (PFE): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Biogen (BIIB) and Pfizer (PFE)
Metric	BIIB	PFE
Revenue Growth (YoY)	2.22%	-1.65%
Revenue Growth (3Y CAGR)	-0.94%	-14.80%
EPS Growth (YoY)	-21.38%	-3.55%
EPS Growth (3Y CAGR)	-25.04%	-37.12%

Financial Strength

Current Ratio (MRQ)

Both Biogen (BIIB) at 1.95 and Pfizer (PFE) at 1.42 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.95

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
BIIB: 1.95
Min: 0.10

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.42

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
PFE: 1.42
Min: 0.10

Biogen (BIIB) vs. Pfizer (PFE): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Biogen (BIIB) at 0.41 carries an industry-typical debt-to-equity mix, while Pfizer (PFE) at 0.71 uses more debt funding than most peers.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.41

Max: 1.42
Q3: 0.65
BIIB: 0.41
Median: 0.15
Q1: 0.02
Min: 0.00

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.71

Max: 1.42
PFE: 0.71
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

Biogen (BIIB) vs. Pfizer (PFE): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Biogen (BIIB) and Pfizer (PFE)
Metric	BIIB	PFE
Current Ratio (MRQ)	1.95	1.42
Debt / Equity (MRQ)	0.41	0.71
Net Debt / EBITDA	1.97	1.97

Dividends

Dividend Yield (TTM)

Biogen (BIIB) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Pfizer (PFE) reports a yield of 7.30%, ranking against industry peers normally.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIIB: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.30%

PFE: 7.30%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Biogen (BIIB) vs. Pfizer (PFE): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Pfizer (PFE) reports payout ratio above 100% at 245.71%, meaning dividends exceeded current-period earnings; Biogen (BIIB) pays no dividend (payout 0.00%).

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIIB: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

245.71%

PFE: 245.71%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Biogen (BIIB) vs. Pfizer (PFE): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Biogen (BIIB) and Pfizer (PFE)
Metric	BIIB	PFE
Dividend Yield (TTM)	0.00%	7.30%
Dividend Payout Ratio (TTM)	0.00%	245.71%

Valuation

P/E Ratio (TTM)

Pfizer (PFE) at 41.99 is near its industry’s usual P/E ratio, while Biogen (BIIB) at 107.51 sits above its peer range — an unusually expensive price for BIIB’s trailing earnings.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

107.51

BIIB: 107.51
Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

41.99

Max: 85.34
Q3: 43.46
PFE: 41.99
Median: 26.69
Q1: 13.30
Min: 0.07

Biogen (BIIB) vs. Pfizer (PFE): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

Pfizer (PFE) at 2.63 sits in the cheaper P/S ratio quartile while Biogen (BIIB) at 3.57 prices around its industry’s middle — PFE costs less per dollar of sales, though read it alongside growth and margins.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.57

Max: 58.18
Q3: 25.77
Median: 7.30
BIIB: 3.57
Q1: 3.01
Min: 0.01

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.63

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
PFE: 2.63
Min: 0.01

Biogen (BIIB) vs. Pfizer (PFE): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

On P/B ratio, both Biogen (BIIB) at 1.94 and Pfizer (PFE) at 1.88 are valued close to their industries’ norm against book — neither stands out from peers.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.94

Max: 13.53
Q3: 6.54
Median: 3.25
BIIB: 1.94
Q1: 1.69
Min: -5.59

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.88

Max: 13.53
Q3: 6.54
Median: 3.25
PFE: 1.88
Q1: 1.69
Min: -5.59

Biogen (BIIB) vs. Pfizer (PFE): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Biogen (BIIB) and Pfizer (PFE)
Metric	BIIB	PFE
P/E Ratio (TTM)	107.51	41.99
P/S Ratio (TTM)	3.57	2.63
P/B Ratio (MRQ)	1.94	1.88
Free Cash Flow Yield (TTM)	2.20%	7.76%